Literature DB >> 33103730

Lowering the risk of Parkinson's disease with GLP-1 agonists and DPP4 inhibitors in type 2 diabetes.

Ece Bayram1, Irene Litvan1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33103730      PMCID： PMC7586082          DOI： 10.1093/brain/awaa287

Source DB:  PubMed          Journal:  Brain        ISSN： 0006-8950            Impact factor:   13.501


× No keyword cloud information.
  9 in total

Review 1.  MDS research criteria for prodromal Parkinson's disease.

Authors:  Daniela Berg; Ronald B Postuma; Charles H Adler; Bastiaan R Bloem; Piu Chan; Bruno Dubois; Thomas Gasser; Christopher G Goetz; Glenda Halliday; Lawrence Joseph; Anthony E Lang; Inga Liepelt-Scarfone; Irene Litvan; Kenneth Marek; José Obeso; Wolfgang Oertel; C Warren Olanow; Werner Poewe; Matthew Stern; Günther Deuschl
Journal:  Mov Disord       Date:  2015-10       Impact factor: 10.338

2.  Diabetes mellitus and Parkinson disease.

Authors:  Gennaro Pagano; Sotirios Polychronis; Heather Wilson; Beniamino Giordano; Nicola Ferrara; Flavia Niccolini; Marios Politis
Journal:  Neurology       Date:  2018-04-06       Impact factor: 9.910

3.  Reduced incidence of Parkinson's disease after dipeptidyl peptidase-4 inhibitors-A nationwide case-control study.

Authors:  Per Svenningsson; Karin Wirdefeldt; Li Yin; Fang Fang; Ioanna Markaki; Suad Efendic; Jonas F Ludvigsson
Journal:  Mov Disord       Date:  2016-07-19       Impact factor: 10.338

4.  Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.

Authors:  Dilan Athauda; Kate Maclagan; Simon S Skene; Martha Bajwa-Joseph; Dawn Letchford; Kashfia Chowdhury; Steve Hibbert; Natalia Budnik; Luca Zampedri; John Dickson; Yazhou Li; Iciar Aviles-Olmos; Thomas T Warner; Patricia Limousin; Andrew J Lees; Nigel H Greig; Susan Tebbs; Thomas Foltynie
Journal:  Lancet       Date:  2017-08-03       Impact factor: 79.321

Review 5.  Update of the MDS research criteria for prodromal Parkinson's disease.

Authors:  Sebastian Heinzel; Daniela Berg; Thomas Gasser; Honglei Chen; Chun Yao; Ronald B Postuma
Journal:  Mov Disord       Date:  2019-08-14       Impact factor: 10.338

6.  Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial.

Authors: 
Journal:  Lancet Neurol       Date:  2015-06-23       Impact factor: 44.182

7.  Exenatide and the treatment of patients with Parkinson's disease.

Authors:  Iciar Aviles-Olmos; John Dickson; Zinovia Kefalopoulou; Atbin Djamshidian; Peter Ell; Therese Soderlund; Peter Whitton; Richard Wyse; Tom Isaacs; Andrew Lees; Patricia Limousin; Thomas Foltynie
Journal:  J Clin Invest       Date:  2013-06       Impact factor: 14.808

Review 8.  Repositioning of dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 agonists as potential neuroprotective agents.

Authors:  Shaker A Mousa; Bassam M Ayoub
Journal:  Neural Regen Res       Date:  2019-05       Impact factor: 5.135

9.  Diabetes, a Contemporary Risk for Parkinson's Disease: Epidemiological and Cellular Evidences.

Authors:  Domenico Sergi; Justine Renaud; Nicola Simola; Maria-Grazia Martinoli
Journal:  Front Aging Neurosci       Date:  2019-11-08       Impact factor: 5.750
  9 in total
  2 in total

Review 1.  Glucagon-Like Peptide 1 Receptor Agonists - Potential Game Changers in the Treatment of Glaucoma?

Authors:  Zaynab Ahmad Mouhammad; Rupali Vohra; Anna Horwitz; Anna-Sophie Thein; Jens Rovelt; Barbara Cvenkel; Pete A Williams; Augusto Azuara-Blanco; Miriam Kolko
Journal:  Front Neurosci       Date:  2022-02-21       Impact factor: 4.677

2.  Attenuated Postprandial GLP-1 Response in Parkinson's Disease.

Authors:  Richard A Manfready; Phillip A Engen; Leo Verhagen Metman; Gabriella Sanzo; Christopher G Goetz; Deborah A Hall; Christopher B Forsyth; Shohreh Raeisi; Robin M Voigt; Ali Keshavarzian
Journal:  Front Neurosci       Date:  2021-07-02       Impact factor: 4.677
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.